Business
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis Interim intent to treat (“ITT”) analysis from Study 108 supports strong durable clinical remission in moderately to severely active ulcerative colitis (“UC”) patients treated with obefazimodFollowing two to four years of open-label treatment with 50 mg, 130 patients de-escal
About this update from Abivax Sa
[{"type":"image","alt":"Abivax","displaySize":"","headline":null,"caption":"Abivax","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/0044215fa29748cca33ccfeb49550e73"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gEy9pkcVet6U4MtRdusZ5w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYy/https://media.zenfs.com/en/globenewswire.com/0044215fa29748cca33ccfeb49550e73","width":300,"height":44},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/gEy9pkcVet6U4MtRdusZ5w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYy/https://media.zenfs.com/en/globenewswire.com/0044215fa29748cca33ccfeb49550e73","width":300,"height":44}},"lazy":false},{"type":"text","content":"Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis","length":224,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Interim intent to treat (“ITT”) analysis from Study 108 supports strong durable clinical remission in moderately to severely active ulcerative colitis (“UC”) patients treated with obefazimod","length":190,"tagName":"p"}]},{"val":[{"type":"text","content":"Following two to four years of open-label treatment with 50 mg, 130 patients de-escalated to 25 mg, and at week 144, 68% (88/130) were in clinical remission and 80% (104/130) completed 144 weeks of treatment","length":208,"tagName":"p"}]},{"val":[{"type":"text","content":"Patients in Study 108 were treated with obefazimod for up to seven years, with no new safety signals observed","length":109,"tagName":"p"}]},{"val":[{"type":"text","content":"ABTECT Phase 3 maintenance trial results expected in late Q2 2026 ","length":65,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents and short-term investments of €491.6M as of March 31, 2026; cash runway into Q4 2027","length":107,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":679,"olType":false},{"type":"text","content":"PARIS, France – May 22, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize th...